Can a common vaccine protect the most vulnerable?
NCT ID NCT07296120
Summary
This study is checking if the RSV vaccine Abrysvo can trigger a protective immune response in adults with blood cancers who have had a stem cell transplant or CAR-T therapy. Researchers will measure antibody levels in the blood before the shot and again four weeks and six months later to see if the vaccine works. The goal is to see if this vaccine can help protect these high-risk patients from serious RSV infection.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RSV IMMUNIZATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cooper University Hospital
Camden, New Jersey, 08103, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.